Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Drops By 55.2%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 312,700 shares, a decrease of 55.2% from the May 15th total of 698,600 shares. Currently, 5.2% of the company’s stock are short sold. Based on an average daily trading volume, of 4,840,000 shares, the days-to-cover ratio is currently 0.1 days.

Shuttle Pharmaceuticals Stock Performance

NASDAQ SHPH traded down $0.06 on Monday, hitting $3.26. 156,757 shares of the stock traded hands, compared to its average volume of 73,172. The firm has a market capitalization of $35.81 million, a price-to-earnings ratio of -0.79 and a beta of -1.10. The business’s fifty day moving average is $6.10 and its two-hundred day moving average is $12.95. Shuttle Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $107.40.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($7.50) earnings per share for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .